Office of Accountability
Read the Office of Accountability report recently issued
PhRMA's Office of Accountability is responsible for receiving comments from the general public and health care professionals regarding Direct to Consumer (DTC) advertisements conducted by any signatory company to the PhRMA Guiding Principles on Direct to Consumer Advertisements About Prescription Medicines. PhRMA’s Chief Medical Officer, Dr. Paul Antony, serves as Director of the Office of Accountability, and supervises the Office’s work. The Office of Accountability reports periodically on the nature of the comments and the companies’ response, and provides copies of these reports to the FDA.
PhRMA's Office of Accountability is responsible for receiving comments from the general public and health care professionals regarding Direct to Consumer (DTC) advertisements conducted by any signatory company to the PhRMA Guiding Principles on Direct to Consumer Advertisements About Prescription Medicines. PhRMA’s Chief Medical Officer, Dr. Paul Antony, serves as Director of the Office of Accountability, and supervises the Office’s work. The Office of Accountability reports periodically on the nature of the comments and the companies’ response, and provides copies of these reports to the FDA.
In April 2006, PhRMA also appointed an independent, voluntary panel of health care providers to review trends in DTC advertising as they relate to the Guiding Principles. The DTC panel's observations and recommendations are outlined in a new report, "DTC Advertising Trends and PhRMA's 'Guiding Principles.' "
Read the Office of Accountability's report recently issued.
Click to read the DTC panel report
Read the Office of Accountability's first report issued in September 2006.
Procedures for Sending Comments to the Office of Accountability
Read the Office of Accountability's report recently issued.
Click to read the DTC panel report
Read the Office of Accountability's first report issued in September 2006.
Procedures for Sending Comments to the Office of Accountability
If you would like to submit a comment to the PhRMA Office of Accountability about a particular DTC advertisement, please follow these steps:
- The Office can only accept comments made in writing (click to view form) and mailed to the PhRMA Office of Accountability, 950 F Street, NW, Washington, DC 20004 or faxed to 202-775-0258.
- The comment should provide information sufficient to identify the company and/or DTC advertisement at issue.
- The comment should relate in some way to an aspect of DTC advertising covered by the Principles.
- Please be sure to include a return address so the Office of Accountability can acknowledge receipt of your comment.
If your comment relates to an aspect of a signatory company’s advertising that is covered by the Principles, the Office of Accountability will forward your comment to the relevant company for consideration.
Additional Resources
DTC Advertising Improvements Observed In Two New Reports
PhRMA released two new reports on DTC advertising, further demonstrating the continuing efforts of America’s pharmaceutical research companies to enhance the education and informative nature of prescription drug ads.
View Press Release
Members Named to PhRMA’S DTC Guiding Principles Review Panel
Pharmaceutical Research and Manufacturers of America (PhRMA) announced four members of its Guiding Principles Independent Review Panel. The panel will review trends in direct to consumer (DTC) advertising as they relate to PhRMA’s voluntary Guiding Principles on Direct to Consumer Advertisements About Prescription Medicines.
View Press Release
PhRMA released two new reports on DTC advertising, further demonstrating the continuing efforts of America’s pharmaceutical research companies to enhance the education and informative nature of prescription drug ads.
View Press Release
Members Named to PhRMA’S DTC Guiding Principles Review Panel
Pharmaceutical Research and Manufacturers of America (PhRMA) announced four members of its Guiding Principles Independent Review Panel. The panel will review trends in direct to consumer (DTC) advertising as they relate to PhRMA’s voluntary Guiding Principles on Direct to Consumer Advertisements About Prescription Medicines.
View Press Release
America’s Pharmaceutical Industry Announces Guidelines on Direct-to-Consumer Advertising
In a major policy speech before the American Legislative Exchange Council’s 32nd Annual Meeting this evening, PhRMA President and CEO Billy Tauzin will announce the pharmaceutical industry’s “Guiding Principles” on direct-to-consumer advertising.
Putting Patients First to Keep Health Care in America the Best in the World
Remarks by Billy Tauzin at The American Legislative Exchange Council Annual Dinner on August 2, 2005.
DTC Voluntary ‘Guiding Principles’ Receive Preliminary Approval by PhRMA Board of Directors
Listening to the concerns of consumers, physicians and other healthcare professionals, the Pharmaceutical Research and Manufacturers of America’s Board of Directors today gave preliminary approval to a set of comprehensive “Guiding Principles” on direct-to-consumer advertising of prescription medicines.
PhRMA Chief Medical Officer Testifies on DTC Advertising
PhRMA Chief Medical Officer Paul Antony testified before Congress at a hearing held by the U.S. Senate Special Committee on Aging on direct-to-consumer advertising and submitted a written statement.